News
March 8, 2023
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
March 1, 2023
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
February 21, 2023
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
January 23, 2023
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
January 5, 2023
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
December 12, 2022
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
December 1, 2022
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
November 22, 2022
TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 11, 2022
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
November 9, 2022